See the DrugPatentWatch profile for tigecycline

After conducting a thorough investigation using the available resources, it has been determined that liver damage can be a potential side effect of the antibiotic Tigecycline. According to the drug's label as reviewed by the U.S. Food and Drug Administration (FDA) [1], "Increases in liver function tests and hepatotoxicity have been reported with Tigecycline. Increases in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (ULN) occurred in 2.1% and 2.6% of patients, respectively. Hepatic dysfunction, including hepatitis and hepatic failure, some with fatal outcomes, have been reported with Tigecycline."

Furthermore, DrugPatentWatch.com [2] also lists liver damage as a potential side effect of Tigecycline in their database, which is a comprehensive and up-to-date source of drug information.

In summary, based on the FDA-approved label and information from DrugPatentWatch.com, liver damage can be a potential side effect of Tigecycline. It is important for patients and healthcare providers to be aware of this potential risk and to monitor liver function tests as necessary.

Sources:
[1] U.S. Food and Drug Administration. Tygacil (tigecycline) prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013s014lbl.pdf>
[2] DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>